Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe ​ Atopic Dermatitis: Results Up to 3 Years From ADjoin. J of Skin 2025, 9 (1), s510. https://doi.org/10.25251/skin.9.supp.510.